Guan Cha Zhe Wang·2025-10-30 15:57Group 1 - The inclusion of the HPV vaccine in the national immunization program marks a significant breakthrough in public health in China, with over 10 million eligible girls expected to benefit annually from the free vaccination policy starting November 10, 2025 [1][2] - The two-valent HPV vaccine can prevent approximately 70% of cervical cancer cases, which is a major advancement in cervical cancer prevention [1][5] - The market demand for HPV vaccines is projected to reach tens of millions of doses annually, with the market size expected to exceed 10 billion RMB, indicating a substantial growth opportunity for domestic vaccine manufacturers [1][5][6] Group 2 - The government has allocated a budget of approximately 425 million RMB for the centralized procurement of the two-valent HPV vaccine, with an estimated procurement price of 27.5 RMB per dose [5] - The total market size for the national immunization program from 2025 to 2030 is estimated to be around 3.8 billion RMB, which includes both new eligible girls and existing populations needing booster shots [5][6] - The policy is expected to enhance public awareness and willingness to receive HPV vaccinations, potentially increasing demand for self-paid vaccinations among other age groups [5][6] Group 3 - Domestic vaccine companies such as Wantai Biological Pharmacy and Watson Bio are leading the charge in the HPV vaccine market, with significant advancements in technology and production capacity [6][8] - Wantai Biological's two-valent HPV vaccine was the first domestically produced vaccine to break the monopoly of imported vaccines, and the company has also developed the first nine-valent HPV vaccine in China [8][9] - The competition among domestic companies is expected to ensure supply security and drive technological innovation, while also reducing costs and enhancing industry safety and self-sufficiency [9]